NEUROINTERVENTIONAL PRODUCTS

Products
NEUROINTERVENTIONAL PRODUCTS
NEUROINTERVENTIONAL PRODUCTS

NEUROINTERVENTIONAL PRODUCTS

Completely self-developed second-generation rapid-exchange balloon dilatation catheter Superior pushability and crossability
NEUROINTERVENTIONAL PRODUCTS
NEUROINTERVENTIONAL PRODUCTS
NEUROINTERVENTIONAL PRODUCTS
NEUROINTERVENTIONAL PRODUCTS
Enquire Now

About Us

Product Description

Stent Platform

  • Fully degradable poly(L-lactide)
  • Sine wave structure in space, In-phase peak-valley connection

Stent Platform

  • Fully degradable poly(L-lactide)
  • Sine wave structure in space, In-phase peak-valley connection



Drug

  • Classical Sirolimus with dose of 15.3ug/mm
  • Inhibit the proliferation and migration of smooth muscle cells


Delivery system

  • Completely self-developed second-generation rapid-exchange balloon dilatation catheter
  • Superior pushability and crossability

About Us

NeoVas RCT Study

The study enrolled 560 subjects in 33 centers from China, Test group(NeoVas): 278 cases, Control group (Xience stent): 282 cases.


Primary endpoint: the late lumen loss in one year follow-up



The clinical result at one year follow-up

The clinical result at Three year follow-up


Conclusion:

The clinical events rate for Neovas bioabsorbable stent is low, showed equal safety and effectiveness with Xience metal stent.

About Us

NeoVas OPC study

The study enrolled 1103 subjects in 45 centers from China, two year clinical follow-up study has been completed to date.


1-2 year follow-up result

2 year stent thrombus: Compare with Absorb and Xience


Conclusion:

2-year follow up Clinical results for 1103 subjects demonstrate that NeoVas bioresorbable stent has equal low clinical events rate. Compared with the first generation bioresorbable stent Absorb BVS, the clinical events rate has been obviously decreased, and it indicates that NeoVas performed favorable safety and effectiveness.

Product list

Product Specifications

  • Stent Diameter (mm)
  • Stent Length (mm)

    8
    12
    16
  • 2.5
  • 3
  • 3.5
  • 4
  • Number of mastoid points
  • 4.5
  • LPRPC4512
    LPRPC4512
    --
  • LPL Series

    (3.5 / 4.0 / 4.5 / 5.0 / 6.0)

  • LPRPC4515
    LPRPC4515
    --
    4
    90
    0
    5
    100
    2
    6
    110
    6

The specification model is indicated as follows:

LP series and sub-series + catheter size composite representationFor example: For a guide catheter with series and sub-series JL3.5, catheter outer diameter 6F, effective working length 100cm, inner diameter 0.070 inches (composite size representation 006-100-070), its specification model is: LPJL3.5006-100-070.

Product list

Product Specifications

  • Pacing mode
  • DDD(R)/VDD(R)/DDI(R)/DVI(R)/DOO(R)/AAI(R)

    AAT(R)/AOO(R)/VVI(R)/VVT(R)/VOO(R)

  • Basic frequency ppm
  • 30.(1)60.(1)100(10 )180

  • Ventricular pulse amplitude V
  • 01(01)3.6 (01 81

  • Ventricular pulse width ms
  • 0.06.0.24;0310.37.0.85;0.92..1.46;1.53;Step size 0.06

  • Image technical parameters
  • a) Standard field of view size: 301.224mmx301.224mm(30305)398.244x293.216mm(3040F)

    b) Image acquisition rate in perspective state: maximum 30fps

    c) Image acquisition rate in photography state: maximum 30fps

    d) Real-time subtraction: maximum 7.5fps

  • Software functions
  • a) Information management

    Enter patient information, examination information, hospital information, and operator information into the device and manage, edit, and print reports

    b) Image acquisition

    It can realize continuous or pulse perspective acquisition;

    it can realize sequential photography acquisition;

    it can realize rotation photography acquisition;

    it can realize step-by-step photography acquisition.

    c) Digital subtraction angiography

    Real-time digital subtraction (image processing) to enhance the imaging function of blood vessels

wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww

Thank You for Your Attention on Lepu Medical!

Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.

Submit
Submit